Sugi Predict

Sugi Predict / Compounds / SCHEMBL123501

SCHEMBL123501

SCHEMBL123501

O=C(Nc1ccnc(Cl)c1)c1ccc(F)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNQ3 O43525 3/20 0.64
▸ KCNQ2 O43526 3/20 0.64
▸ KCNE1 P15382 3/20 0.64
▸ KCNQ1 P51787 3/20 0.64
▸ BACE1 P56817 1/20 0.64
▸ KMT2A Q03164 2/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ GRM5 P41594 2/20 0.58
▸ HDAC4 P56524 1/20 0.58
▸ SMARCA2 P51531 4/20 0.55
▸ SMARCA4 P51532 3/20 0.55
▸ KCNK3 O14649 1/20 0.55
▸ KCNK9 Q9NPC2 1/20 0.55
▸ PTPN1 P18031 1/20 0.53
▸ CYP11B1 P15538 1/20 0.52
▸ CYP11B2 P19099 1/20 0.52
▸ MITF O75030 1/20 0.51
▸ P4HTM Q9NXG6 1/20 0.51
▸ EGFR P00533 1/20 0.51
▸ ERBB3 P21860 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28577238 0.86 SMARCA2 (0.56) KCNQ3KCNQ2KCNE1KCNQ1BACE1
SCHEMBL28821933 0.84 JAK2 (0.63) KCNQ3KCNQ2KMT2AMEN1HDAC4
SCHEMBL22125204 0.83 SMARCA2 (0.74) KMT2AMEN1GRM5SMARCA2SMARCA4
SCHEMBL14051567 0.82 NPC1 (0.60) KMT2AMEN1HDAC4SMARCA2SMARCA4
SCHEMBL13988883 0.82 HDAC4 (0.55) KCNQ3KCNQ2KCNE1KCNQ1BACE1
SCHEMBL4250912 0.80 KCNQ3 (0.70) KCNQ3KCNQ2KCNE1KCNQ1HDAC4
SCHEMBL19351872 0.78 MEN1 (0.54) KCNQ3KCNQ2KCNE1KCNQ1KMT2A
SCHEMBL5214418 0.78 KCNQ3 (1.00) KCNQ3KCNQ2KCNE1KCNQ1BACE1
SCHEMBL14082276 0.78 TRPV1 (0.60) HDAC4SMARCA2SMARCA4KCNK3KCNK9
SCHEMBL16430855 0.78 KCNQ3 (0.66) KCNQ3KCNQ2KCNE1KCNQ1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110041302-B 2-amino-4-substituted pyridine derivative and synthesis method and application thereof 南方医科大学 2021-11-30 — — CN disclosed
CN-102325753-B Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL MYERS SQUIBB CO 2014-09-10 — — CN disclosed
EP-2391602-B1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-12-04 — — EP disclosed
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 — — US disclosed
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 — — US disclosed
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 — — US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
CN-102325753-A Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL MYERS SQUIBB CO 2012-01-18 — — CN disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 — — US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 — — US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 — — US disclosed
EP-2391602-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-12-07 — — EP disclosed
WO-2010080481-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 — — WO disclosed
WO-2010080481-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 — — WO disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 — — US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 — — US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 KCNQ3 2090/4885KCNQ2 2246/4885KCNE1 1749/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 KCNQ3 2090/4885KCNQ2 2246/4885KCNE1 1749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.